{
    "xml": "<topic id=\"PHP1508\" outputclass=\"drug\" rev=\"1.12\" type=\"drug\" namespace=\"/drugs/apixaban\" basename=\"apixaban\" title=\"APIXABAN\">\n<title>APIXABAN</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1217\" namespace=\"/interactions/list-of-drug-interactions/anticoagulants/apixaban\">Apixaban</xref>\n</p>\n<data name=\"vtmid\">703906002</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_541694731\" title=\"Factor Xa inhibitors\">Factor Xa inhibitors</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP73514\" outputclass=\"drugAction\" rev=\"1.7\" parent=\"/drugs/apixaban\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Apixaban is a direct inhibitor of activated factor X (factor Xa).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP73489\" outputclass=\"indicationsAndDose\" rev=\"1.49\" parent=\"/drugs/apixaban\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prophylaxis of venous thromboembolism following knee replacement surgery</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>2.5&#8239;mg twice daily for 10&#8211;14 days, to be started 12&#8211;24 hours after surgery.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prophylaxis of venous thromboembolism following hip replacement surgery</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>2.5&#8239;mg twice daily for 32&#8211;38 days, to be started 12&#8211;24 hours after surgery.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of deep-vein thrombosis</p>\n<p outputclass=\"therapeuticIndication\">Treatment of pulmonary embolism</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 10&#8239;mg twice daily for 7 days, then maintenance 5&#8239;mg twice daily.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prophylaxis of recurrent deep-vein thrombosis</p>\n<p outputclass=\"therapeuticIndication\">Prophylaxis of recurrent pulmonary embolism</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>2.5&#8239;mg twice daily, following completion of 6 months anticoagulant treatment.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation and at least one risk factor such as previous stroke or transient ischaemic attack, symptomatic heart failure, diabetes mellitus, hypertension, or age &#8805; 75 years</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult 18&#8211;79 years</p>\n<p>5&#8239;mg twice daily.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult 80 years and over (body-weight up to 61 kg)</p>\n<p>2.5&#8239;mg twice daily.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"doseEquivalence\">\n<title>Dose equivalence and conversion</title>\n<p>For information on changing from, or to, other anticoagulants, consult product literature.</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP73523\" outputclass=\"contraindications\" rev=\"1.9\" parent=\"/drugs/apixaban\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Active bleeding</ph>; <ph outputclass=\"contraindication\">malignant neoplasms</ph>; <ph outputclass=\"contraindication\">oesophageal varices</ph>; <ph outputclass=\"contraindication\">recent brain surgery</ph>; <ph outputclass=\"contraindication\">recent gastro-intestinal ulcer</ph>; <ph outputclass=\"contraindication\">recent intracranial haemorrhage</ph>; <ph outputclass=\"contraindication\">recent ophthalmic surgery</ph>; <ph outputclass=\"contraindication\">recent spine surgery</ph>; <ph outputclass=\"contraindication\">significant risk of major bleeding</ph>; <ph outputclass=\"contraindication\">vascular aneurysm</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP73532\" outputclass=\"cautions\" rev=\"1.9\" parent=\"/drugs/apixaban\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Anaesthesia with postoperative indwelling epidural catheter (risk of paralysis&#8212;monitor neurological signs and wait 20&#8211;30 hours after apixaban dose before removing catheter and do not give next dose until at least 5 hours after catheter removal)</ph>; <ph outputclass=\"caution\">prosthetic heart valve (efficacy not established)</ph>; <ph outputclass=\"caution\">risk of bleeding</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP73485\" outputclass=\"interactions\" rev=\"1.11\" parent=\"/drugs/apixaban\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (apixaban).</p>\n<p>Caution in concomitant use of drugs that increase risk of bleeding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP73461\" outputclass=\"sideEffects\" rev=\"1.19\" parent=\"/drugs/apixaban\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Anaemia</ph>; <ph outputclass=\"sideEffect\">bruising</ph>; <ph outputclass=\"sideEffect\">haemorrhage</ph>; <ph outputclass=\"sideEffect\">nausea</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Hypotension</ph>; <ph outputclass=\"sideEffect\">rash</ph>; <ph outputclass=\"sideEffect\">thrombocytopenia</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP73477\" outputclass=\"pregnancy\" parent=\"/drugs/apixaban\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP73538\" outputclass=\"breastFeeding\" parent=\"/drugs/apixaban\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;present in milk in <i>animal </i>studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP73506\" outputclass=\"hepaticImpairment\" parent=\"/drugs/apixaban\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid in severe impairment and in hepatic disease associated with coagulopathy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP73470\" outputclass=\"renalImpairment\" parent=\"/drugs/apixaban\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>For <i>prophylaxis of stroke and systemic embolism in atrial fibrillation</i>, reduce dose to 2.5&#8239;mg twice daily if creatinine clearance 15&#8211;29&#8239;mL/minute, or if serum-creatinine &#8805;133&#8239; micromol/litre and age &#8805;80 years or body-weight &#8804;60&#8239;kg.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>For <i>prophylaxis of venous thromboembolism following knee or hip replacement surgery, prophylaxis of recurrent deep-vein thrombosis or pulmonary embolism, and treatment of deep-vein thrombosis or pulmonary embolism</i>, use with caution if creatinine clearance 15&#8211;29&#8239;mL/ minute.</p>\n<p>Manufacturer advises avoid if creatinine clearance less than 15&#8239;mL/minute&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP73446\" outputclass=\"monitoringRequirements\" parent=\"/drugs/apixaban\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Patients should be monitored for signs of bleeding or anaemia; treatment should be stopped if severe bleeding occurs.</p>\n<p>No routine anticoagulant monitoring required (INR tests are unreliable).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP57173\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.15\" parent=\"/drugs/apixaban\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p>Duration of treatment should be determined by balancing the benefit of treatment with the bleeding risk; shorter duration of treatment (at least 3 months) should be based on transient risk factors i.e recent surgery, trauma, immobilsation.</p>\n<p>Apixaban should not be used as an alternative to unfractionated heparin in pulmonary embolism in patients with haemodynamic instability, or who may receive thrombolysis or pulmonary embolectomy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP73433\" outputclass=\"nationalFunding\" rev=\"1.37\" parent=\"/drugs/apixaban\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA245</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults (January 2012)</p>\r\n<p>Apixaban is an option for the prevention of venous thromboembolism in adults after elective hip or knee replacement surgery.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA245\">www.nice.org.uk/TA245</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA275</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Apixaban for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation (February 2013)</p>\r\n<p>Apixaban is an option for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation in accordance with its licensed indication; with one or more of the following risk factors: </p>\r\n<ul>\r\n<li>previous stroke or transient ischaemic attack</li>\r\n<li>symptomatic heart failure</li>\r\n<li>age &#8805;75 years</li>\r\n<li>diabetes mellitus</li>\r\n<li>hypertension</li>\r\n</ul>\r\n<p>The risks and benefits of apixaban compared to warfarin, dabigatran etexilate, and rivaroxaban should be discussed with the patient.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA275\">www.nice.org.uk/TA275</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA341</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (June 2015)</p>\r\n<p>Apixaban is an option for the treatment and prevention of recurrent deep vein thrombosis and pulmonary embolism in adults.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA341\">www.nice.org.uk/TA341</xref>\n</sectiondiv>\n</sectiondiv>\r\n </section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP1508-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/apixaban\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77311\" title=\"Tablet\" namespace=\"/drugs/apixaban/tablet\">Tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP107699\" namespace=\"/about/changes\" title=\"Changes\" count=\"1\" rel=\"backlink\">Changes</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP98619\" namespace=\"/guidance/prescribing-in-dental-practice\" title=\"Prescribing in dental practice\" count=\"1\" rel=\"backlink\">Prescribing in dental practice</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78291\" namespace=\"/treatment-summaries/arrhythmias\" title=\"Arrhythmias\" count=\"1\" rel=\"backlink\">Arrhythmias</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78403\" namespace=\"/treatment-summaries/venous-thromboembolism\" title=\"Venous thromboembolism\" count=\"1\" rel=\"backlink\">Venous thromboembolism</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1217\" namespace=\"/interactions/list-of-drug-interactions/anticoagulants/apixaban\" title=\"Apixaban\" count=\"1\" rel=\"link\">Apixaban</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77311\" namespace=\"/drugs/apixaban/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n</links>\n</topic>",
    "id": "PHP1508",
    "outputclass": "drug",
    "rev": "1.12",
    "type": "drug",
    "namespace": "/drugs/apixaban",
    "basename": "apixaban",
    "title": "APIXABAN",
    "interactants": [
        {
            "id": "bnf_int_1217",
            "label": "Apixaban"
        }
    ],
    "vtmid": "703906002",
    "drugClassification": [
        "Factor Xa inhibitors"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Apixaban is a direct inhibitor of activated factor X (factor Xa).",
                "html": "<p>Apixaban is a direct inhibitor of activated factor X (factor Xa).</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Prophylaxis of venous thromboembolism following knee replacement surgery",
                        "html": "Prophylaxis of venous thromboembolism following knee replacement surgery"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "2.5 mg twice daily for 10&#8211;14 days, to be started 12&#8211;24 hours after surgery.",
                        "html": "<p>2.5&#8239;mg twice daily for 10&#8211;14 days, to be started 12&#8211;24 hours after surgery.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prophylaxis of venous thromboembolism following hip replacement surgery",
                        "html": "Prophylaxis of venous thromboembolism following hip replacement surgery"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "2.5 mg twice daily for 32&#8211;38 days, to be started 12&#8211;24 hours after surgery.",
                        "html": "<p>2.5&#8239;mg twice daily for 32&#8211;38 days, to be started 12&#8211;24 hours after surgery.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Treatment of deep-vein thrombosis",
                        "html": "Treatment of deep-vein thrombosis"
                    },
                    {
                        "textContent": "Treatment of pulmonary embolism",
                        "html": "Treatment of pulmonary embolism"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 10 mg twice daily for 7 days, then maintenance 5 mg twice daily.",
                        "html": "<p>Initially 10&#8239;mg twice daily for 7 days, then maintenance 5&#8239;mg twice daily.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prophylaxis of recurrent deep-vein thrombosis",
                        "html": "Prophylaxis of recurrent deep-vein thrombosis"
                    },
                    {
                        "textContent": "Prophylaxis of recurrent pulmonary embolism",
                        "html": "Prophylaxis of recurrent pulmonary embolism"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "2.5 mg twice daily, following completion of 6 months anticoagulant treatment.",
                        "html": "<p>2.5&#8239;mg twice daily, following completion of 6 months anticoagulant treatment.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation and at least one risk factor such as previous stroke or transient ischaemic attack, symptomatic heart failure, diabetes mellitus, hypertension, or age &#8805; 75 years",
                        "html": "Prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation and at least one risk factor such as previous stroke or transient ischaemic attack, symptomatic heart failure, diabetes mellitus, hypertension, or age &#8805; 75 years"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "5 mg twice daily.",
                        "html": "<p>5&#8239;mg twice daily.</p>",
                        "ageGroup": "18&#8211;79 years"
                    },
                    {
                        "textContent": "2.5 mg twice daily.",
                        "html": "<p>2.5&#8239;mg twice daily.</p>",
                        "ageGroup": "80 years and over (body-weight up to 61 kg)"
                    }
                ]
            }
        ],
        "doseEquivalence": [
            {
                "type": "doseEquivalence",
                "title": "Dose equivalence and conversion",
                "textContent": "For information on changing from, or to, other anticoagulants, consult product literature.",
                "html": "<p>For information on changing from, or to, other anticoagulants, consult product literature.</p>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Active bleeding",
                "html": "Active bleeding"
            },
            {
                "type": "contraindications",
                "textContent": "malignant neoplasms",
                "html": "malignant neoplasms"
            },
            {
                "type": "contraindications",
                "textContent": "oesophageal varices",
                "html": "oesophageal varices"
            },
            {
                "type": "contraindications",
                "textContent": "recent brain surgery",
                "html": "recent brain surgery"
            },
            {
                "type": "contraindications",
                "textContent": "recent gastro-intestinal ulcer",
                "html": "recent gastro-intestinal ulcer"
            },
            {
                "type": "contraindications",
                "textContent": "recent intracranial haemorrhage",
                "html": "recent intracranial haemorrhage"
            },
            {
                "type": "contraindications",
                "textContent": "recent ophthalmic surgery",
                "html": "recent ophthalmic surgery"
            },
            {
                "type": "contraindications",
                "textContent": "recent spine surgery",
                "html": "recent spine surgery"
            },
            {
                "type": "contraindications",
                "textContent": "significant risk of major bleeding",
                "html": "significant risk of major bleeding"
            },
            {
                "type": "contraindications",
                "textContent": "vascular aneurysm",
                "html": "vascular aneurysm"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Anaesthesia with postoperative indwelling epidural catheter (risk of paralysis&#8212;monitor neurological signs and wait 20&#8211;30 hours after apixaban dose before removing catheter and do not give next dose until at least 5 hours after catheter removal)",
                "html": "Anaesthesia with postoperative indwelling epidural catheter (risk of paralysis&#8212;monitor neurological signs and wait 20&#8211;30 hours after apixaban dose before removing catheter and do not give next dose until at least 5 hours after catheter removal)"
            },
            {
                "type": "cautions",
                "textContent": "prosthetic heart valve (efficacy not established)",
                "html": "prosthetic heart valve (efficacy not established)"
            },
            {
                "type": "cautions",
                "textContent": "risk of bleeding",
                "html": "risk of bleeding"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (apixaban).\n\nCaution in concomitant use of drugs that increase risk of bleeding.",
                "html": "<p>Appendix 1 (apixaban).</p><p>Caution in concomitant use of drugs that increase risk of bleeding.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Anaemia",
                        "html": "Anaemia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "bruising",
                        "html": "bruising",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "haemorrhage",
                        "html": "haemorrhage",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Hypotension",
                        "html": "Hypotension",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "thrombocytopenia",
                        "html": "thrombocytopenia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;no information available.",
                "html": "<p>Manufacturer advises avoid&#8212;no information available.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;present in milk in animal studies.",
                "html": "<p>Manufacturer advises avoid&#8212;present in milk in <i>animal </i>studies.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid in severe impairment and in hepatic disease associated with coagulopathy.",
                "html": "<p>Avoid in severe impairment and in hepatic disease associated with coagulopathy.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "For prophylaxis of stroke and systemic embolism in atrial fibrillation, reduce dose to 2.5 mg twice daily if creatinine clearance 15&#8211;29 mL/minute, or if serum-creatinine &#8805;133 micromol/litre and age &#8805;80 years or body-weight &#8804;60 kg.",
                "html": "<p>For <i>prophylaxis of stroke and systemic embolism in atrial fibrillation</i>, reduce dose to 2.5&#8239;mg twice daily if creatinine clearance 15&#8211;29&#8239;mL/minute, or if serum-creatinine &#8805;133&#8239; micromol/litre and age &#8805;80 years or body-weight &#8804;60&#8239;kg.</p>"
            }
        ],
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "For prophylaxis of venous thromboembolism following knee or hip replacement surgery, prophylaxis of recurrent deep-vein thrombosis or pulmonary embolism, and treatment of deep-vein thrombosis or pulmonary embolism, use with caution if creatinine clearance 15&#8211;29 mL/ minute.\n\nManufacturer advises avoid if creatinine clearance less than 15 mL/minute&#8212;no information available.",
                "html": "<p>For <i>prophylaxis of venous thromboembolism following knee or hip replacement surgery, prophylaxis of recurrent deep-vein thrombosis or pulmonary embolism, and treatment of deep-vein thrombosis or pulmonary embolism</i>, use with caution if creatinine clearance 15&#8211;29&#8239;mL/ minute.</p><p>Manufacturer advises avoid if creatinine clearance less than 15&#8239;mL/minute&#8212;no information available.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Patients should be monitored for signs of bleeding or anaemia; treatment should be stopped if severe bleeding occurs.\n\nNo routine anticoagulant monitoring required (INR tests are unreliable).",
                "html": "<p>Patients should be monitored for signs of bleeding or anaemia; treatment should be stopped if severe bleeding occurs.</p><p>No routine anticoagulant monitoring required (INR tests are unreliable).</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "textContent": "Duration of treatment should be determined by balancing the benefit of treatment with the bleeding risk; shorter duration of treatment (at least 3 months) should be based on transient risk factors i.e recent surgery, trauma, immobilsation.\n\nApixaban should not be used as an alternative to unfractionated heparin in pulmonary embolism in patients with haemodynamic instability, or who may receive thrombolysis or pulmonary embolectomy.",
                "html": "<p>Duration of treatment should be determined by balancing the benefit of treatment with the bleeding risk; shorter duration of treatment (at least 3 months) should be based on transient risk factors i.e recent surgery, trauma, immobilsation.</p><p>Apixaban should not be used as an alternative to unfractionated heparin in pulmonary embolism in patients with haemodynamic instability, or who may receive thrombolysis or pulmonary embolectomy.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA245",
                        "label": "www.nice.org.uk/TA245"
                    }
                ],
                "fundingIdentifier": "NICE TA245",
                "textContent": "Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults (January 2012) Apixaban is an option for the prevention of venous thromboembolism in adults after elective hip or knee replacement surgery.\n\nwww.nice.org.uk/TA245",
                "html": "<p outputclass=\"title\">Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults (January 2012)</p> <p>Apixaban is an option for the prevention of venous thromboembolism in adults after elective hip or knee replacement surgery.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA245\">www.nice.org.uk/TA245</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA275",
                        "label": "www.nice.org.uk/TA275"
                    }
                ],
                "fundingIdentifier": "NICE TA275",
                "textContent": "Apixaban for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation (February 2013) Apixaban is an option for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation in accordance with its licensed indication; with one or more of the following risk factors: previous stroke or transient ischaemic attack symptomatic heart failure age &#8805;75 years diabetes mellitus hypertension The risks and benefits of apixaban compared to warfarin, dabigatran etexilate, and rivaroxaban should be discussed with the patient.\n\nwww.nice.org.uk/TA275",
                "html": "<p outputclass=\"title\">Apixaban for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation (February 2013)</p> <p>Apixaban is an option for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation in accordance with its licensed indication; with one or more of the following risk factors: </p> <ul> <li>previous stroke or transient ischaemic attack</li> <li>symptomatic heart failure</li> <li>age &#8805;75 years</li> <li>diabetes mellitus</li> <li>hypertension</li> </ul> <p>The risks and benefits of apixaban compared to warfarin, dabigatran etexilate, and rivaroxaban should be discussed with the patient.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA275\">www.nice.org.uk/TA275</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA341",
                        "label": "www.nice.org.uk/TA341"
                    }
                ],
                "fundingIdentifier": "NICE TA341",
                "textContent": "Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (June 2015) Apixaban is an option for the treatment and prevention of recurrent deep vein thrombosis and pulmonary embolism in adults.\n\nwww.nice.org.uk/TA341",
                "html": "<p outputclass=\"title\">Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (June 2015)</p> <p>Apixaban is an option for the treatment and prevention of recurrent deep vein thrombosis and pulmonary embolism in adults.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA341\">www.nice.org.uk/TA341</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP77311",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "treatmentSummary": [
            {
                "id": "PHP107699",
                "label": "Changes",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP98619",
                "label": "Prescribing in dental practice",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78291",
                "label": "Arrhythmias",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78403",
                "label": "Venous thromboembolism",
                "type": "treatmentSummary"
            }
        ],
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1217",
                "label": "Apixaban",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP77311",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    }
}